By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Immune Pharmaceuticals, Inc. 

150 Broadway
Suite 1801
New York  New York  10038  U.S.A.
Phone: 646-937-1941 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Immune Pharma Appoints Tony Fiorino, MD, PhD As Chief Medical Officer And Chief Operating Officer 8/14/2017 6:17:27 AM
Cytovia, Inc. (MAXM), Immune Pharma’s Oncology Subsidiary, Announces Publication Of Results Showing Anti-Metastatic Properties Of Its Lead Drug Ceplene And Filing Of A New Worldwide Patent 8/10/2017 7:51:48 AM
Cytovia, Inc. (MAXM), Immune Pharma’s Oncology Subsidiary, Announces The Publication Of New Results In The British Journal Of Haematology And Filing Of A World-Wide Patent Protecting The Use Of Ceplene In Chronic Myeloid Leukemia (CML) 8/7/2017 9:07:36 AM
Immune Pharma Issues Letter To Shareholders 8/4/2017 11:36:22 AM
Immune Pharma Provides Update On Plan To Implement A Spin-Off Of Cytovia, Inc. (MAXM) Into A Separate Publicly Traded Oncology Company 7/19/2017 7:46:57 AM
Immune Pharma’ Oncology Subsidiary, Cytovia, Inc. (MAXM), Announces The Filing Of A World-Wide Patent Protecting The Use Of Ceplene In Acute Myeloid Leukemia (AML) And Other Hematological Cancers With Mutated NPM1 7/13/2017 6:13:45 AM
Cytovia, Inc. (MAXM), Immune Pharma’ Oncology Subsidiary, Enters Into A Definitive Agreement With Pint Pharma For The Licensing And Commercialization Of Ceplene In Latin America 7/12/2017 7:24:34 AM
Immune Pharma's Oncology Subsidiary, Cytovia, Inc. (MAXM), Announces Additional Clinical Trial Results On The Efficacy Of Ceplene In Combination With Low-Dose IL-2 In Patients With Acute Myeloid Leukemia, Recently Published In Leukemia, A Leading Hematology Journal 7/5/2017 7:22:04 AM
Immune Pharma's Oncology Subsidiary, Cytovia, Inc. (MAXM) Provides Update To Proposed Pint Pharma Transaction: Substantial Agreement Reached On Material Terms Of The Licensing And Commercialization Of Ceplene In Latin America 6/29/2017 7:35:51 AM
Immune Pharma Announces Initiation Of Enrollment In Clinical Trial With Ceplene/ Low-Dose IL-2 In Chronic Myelomonocytic Leukemia (CMML) 6/20/2017 7:30:35 AM
12345678910...
//-->